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Abstract. all mammalian cells contain one or more members 
of the facilitative glucose transporter (GluT) gene family. 
Glucose transporter membrane proteins (GluT) regulate 
the movement of glucose between the extracellular and 
intracellular compartments, maintaining a constant supply 
of glucose available for metabolism. Tumor cells are highly 
energy-dependent, therefore GluT overexpression is often 
observed. in fact, overexpression of GluT1 has been corre-
lated with hypoxia markers in several tumor types, including 
renal cell carcinoma (rcc). We retrospectively analyzed 80 
paraffin-embedded RCC samples. The pattern of GLUT1-5 
expression in rcc specimens was evaluated using tissue-
array technology and correlated with histological tumor 
characteristics. Pathological parameters included tumor 
location, renal pelvis, vein and lymph vessel invasion, capsule 
breakage, histological subtype, Furhman grade, hilar invasion 
and tumor stage at diagnosis. The expression of five facilita-
tive glucose transporters, GluT1 (erythrocyte type), GluT2 
(liver type), GluT3 (brain type), GluT4 (muscle/fat type) 
and GluT5 (small intestinal type), was semi-quantitatively 
analyzed. in non-parametric, Mann-Whitney u and Kruskal-
Wallis tests, a significant positive correlation was consistently 
found between moderately differentiated rcc tissues and the 
expression of GluT5 (p=0.024). Patients who had pelvic inva-
sion and capsule breakage at diagnosis also showed increased 
GluT5 expression levels (p=0.039 and p=0.019, respec-
tively). Moreover, GLUT5 showed statistical significance in 
those samples identified as being of clear cell histological 
type (p=0.001). a high expression of GluT5 in human rcc 
was observed. GluT5 appears to be correlated with grade ii 
differentiation, locoregional invasion and aggressiveness, and 
may play a role in rcc development.
Introduction
The worldwide incidence of renal cell carcinoma (rcc) 
has increased in the past three decades (1). its frequency is 
higher in men than in women (2). it is estimated that 63,300 
and 54,390 patients are diagnosed every year in the eu and 
uS, respectively, of which 39,000 eventually succumb to the 
disease (3,4).
Glucose metabolism is a central component of living 
systems; the oxidation of glucose represents a major source of 
metabolic energy for mammalian cells. However, tumor cells 
have a reduced ability to use oxidative metabolism and rely 
instead on an increased rate of glycolysis and glucose use (5). a 
more active glycolytic metabolism is reflected in an increased 
rate of glucose uptake (6). This differential glucose uptake 
between normal and tumor cells is the basis for the diagnosis 
of various tumors by positron emission tomography using the 
glucose analogue fluorine-18-fluorodeoxyglucose (7).
Since plasma membrane is impermeable to polar mole-
cules such as glucose, glucose uptake necessitates the use of 
membrane-associated carrier proteins.
The glucose transporter (GluT) protein family consists 
of 14 members grouped into three major classes based on 
sequence homology and substrate selectivity (8). GluT 
proteins mediate the transport of glucose and other mono-
saccharides into and out of mammalian cells according to a 
concentration gradient (9). GluT transporters have different 
expression patterns in different tissues and play various roles 
according to substrate specificities, kinetic properties, function 
and developmental regulation. The expression of five facilita-
tive glucose transporter genes, GLUT1 (erythrocyte type), 
GLUT2 (liver type), GLUT3 (brain type), GLUT4 (muscle/
fat type) and GLUT5 (small intestine type), is relatively tissue 
specific. Certain tissues and cells express two or even more 
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glucose transporter isoforms, indicating that the organism 
has developed a backup system guaranteeing adequate energy 
supply (10). Several members of the GluT family transport 
not only glucose, but also fructose (GluT2, -5, -7, -8, -9, -11 
and -12), except GluT5, which exclusively transports fruc-
tose.
it is currently accepted that the increase in glucose uptake 
observed in malignant cells is associated with the overexpres-
sion of GluTs. oncogenes and growth factors are responsible 
for GluT overexpression in malignant cells (8). increase in 
glucose transport and metabolism may reflect an adaptative 
requirement by these rapidly growing cells for more sources 
of energy (11). Glucose provides much-needed energy for the 
cells in the following ways: it serves as a primary substrate 
for the generation of aTP, supplies a carbon source for the 
synthesis of other macronutrients, such as nucleic acids and 
phospholipids, and is metabolized by the pentose phosphate 
pathway to generate nadPH.
GluTs transport glucose, and increased expression of 
these transporters has been reported in various tumor types. 
GluT1 has been found overexpressed in breast, colorectal, 
lung, and ovarian carcinoma (12), GluT12 in breast cancer 
(13) and GluT3 in lung, ovarian and gastric cancers (14).
less is known regarding the role of the GluT system in 
rcc development. Previous studies (15) compared normal 
kidney and rcc tissue samples in terms of expression levels 
of GluT members measured by reverse transcriptase-
polymerase chain reaction (rT-Pcr). While kidney normal 
tissue expressed all the GLUT isoforms in the medium range, 
it was shown that, in clear cell rcc, the expression of GLUT1 
was increased significantly. However, the levels of expression 
of GLUT4, 9 and 12 were found to be decreased. GLUT4 
was also found to be elevated in chromophobe histological 
subtypes. a study of 187 tumor tissue samples of kidney 
cancer (16) also found that GluT1 expression, measured by 
immunohistochemistry in a panel of tissue microarrays, was 
correlated with a reduced overall survival and higher levels of 
hypoxia-inducible factor-1 (HiF-1α).
However, these findings have uncertain clinical signifi-
cance, and could not be correlated in a prospective manner 
when fluorine-18-fluorodeoxyglucose-positron emission 
tomography (FdG-PeT) was used as a diagnostic technique 
in 19 patients before nephrectomy. only 6 out of the 19 histo-
logically confirmed patients had a positive FDG-PET result, 
therefore the clinical and biological significance of GLUT1 
expression in kidney cancer has yet to be determined (17). The 
aim of the present study was to determine the immunohis-
tochemical pattern of expression of the glucose transporters 
1, 2, 3, 4 and 5 (GluT1-5) using a tissue array (Ta) in tumor 
tissue samples with different rcc histological subtypes, and 
to evaluate whether GluT1-5 expression correlates with 
different histopathological parameters: tumor location, renal 
pelvis, vein and lymph vessel invasion, capsule breakage, 
histological subtype, Furhman grade, hilar invasion and tumor 
stage.
Materials and methods
Patients and tumor samples. The clinical and pathological 
data of patients who were diagnosed with rcc and underwent 
surgery at the department of urology of Modelo Hospital, 
a coruña, Spain, from 1996 to 2007, were reviewed. The 
study group consisted of 80 patients whose original patholog-
ical specimens were available for evaluation. The institutional 
review Board of Modelo Hospital approved the retrospective 
review of the medical records and the use of archived tumor 
specimens.
Tissue microarray generation. all archival tissue samples 
were routinely fixed in formalin and embedded in paraffin. 
representative tissue areas were marked on standard H&e 
sections, punched out of the paraffin block using a 2.0-mm 
punch and inserted in a recipient paraffin block to produce 
a 6x8 array of 48 cases. a normal cerebellum tissue sample 
was inserted as a negative control. When possible, triplicate 
cores per specimen were arrayed on a recipient paraffin block 
in order to decrease the error introduced by sampling and to 
minimize the impact of tissue during processing. Sections (4 
µm) were cut from the completed array blocks and transferred 
to silanized glass slides.
Immunohistochemistry. The working dilution was determined 
using positive controls, as indicated in the literature. For 
GluT1, esophagus was used; for GluT2, liver was used; for 
GluT3, placenta was used, for GluT4, heart was used and 
for GluT5, small intestine was used. additional sections, 
run in parallel, but with the omission of the primary antibody, 
served as negative controls.
The tissue sections were deparaffinized by incubation in 
xylene and rehydrated in a graded series of ethanol and water 
solutions. The antigen was retrieved with 0.01 M citrate buffer 
(pH 6.0) by heating the samples in a microwave vacuum 
histoprocessor (2100 retriever™; Pickcell laboratories) 
at a controlled final temperature of 121˚C for 15 min. The 
primary antibodies were diluted in dako antibody diluent 
(dakocytomation) with background-reducing components 
and were used at the followings dilutions: GluT1-2, 1:50, 
GluT3, 1:25 and GluT4-5, 1:250 (all abcam). The primary 
antibodies were incubated at room temperature for 30 min and 
detected using the dako enVision system and diaminobenzi-
dine according to the manufacturer's instructions.
Semi-quantification of antibody staining. The immuno-
reactivity score was evaluated, following other groups, by 
multiplying the percentage of positive cells (PP percentage) 
and the staining intensity (Si). First, the PP percentage was 
scored as: 0, <1%; 1, 1-24%; 2, 25-49%; 3, 50-74%; and 4, 
≥75%. Second, the SI was scored as: 1, weak; 2, medium; and 
3, intense staining.
each slide was carefully examined in the area of the tumor 
that contained the greatest fraction of positively stained cancer 
cells.
Statistical analysis. data are expressed as the mean ± standard 
deviation (SD). The statistical significance of the differences 
found was evaluated at the 95% confidence level by non-
parametric statistical, Mann-Whitney u and Kruskal-Wallis 
tests. p-values of <0.05 were considered the cut-off point for 
significance. All statistical analyses were performed using 
commercially available software (SPSS 17.0 for Windows).
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Results
The clinical characteristics of the patients are detailed in 
Table i. The expression of GluT isoforms was analyzed by 
immunohistochemistry in the tumor tissue samples (Figs. 1-3).
GluT1 showed membranous staining in red blood cells 
(Fig. 1a). Positive but weaker staining was also observed in 
38 of 80 (47.5%) rcc samples (Fig. 1a), in which GluT1 
staining was observed in the plasmatic membrane and 
cytoplasm. Tubular epithelium, glomerulus and interstice 
were negative for GluT1 staining. There was no correlation 
between GluT1 staining and the pathological parameters 
considered for review such as grade of differentiation, pelvic 
invasion and capsule breakage (Table ii).
GluT2 was detected as a strong reaction in the cell 
membrane in 58/80 (72.5%) rcc samples. a cytoplasmic 
reaction was observed with moderate intensity in 27.5% of the 
RCC samples (Fig. 1B). No significant correlation between the 
histological parameters studied and the expression of GluT2 
was observed (Table ii).
GluT3 was detected in 30/80 (37.6%) rcc samples, 
showing a weak cell membrane reaction and granular cyto-
plasmic staining (Fig. 2A). No significant correlation between 
the histological parameters studied and the expression of 
GluT2 or GluT3 was observed (Table ii). 
GluT4 was detected in a weak cytoplasmic pattern in 
45/80 (56.3%) RCC samples (Fig. 2B). Patients classified as T4 
showed increased GluT4 expression (p=0.029). 
By contrast, GluT5 showed high intensity in the 
membrane and cytoplasm of tumoral cells in 46/80 (57.6%) 
rcc samples (Fig. 3B and c). in normal kidney, the intensity 
reaction on the apical pole of tubular epithelium (Fig. 3a), 
vascular endothelium, glomerulus and interstice was negative. 
A significant positive correlation was found between moder-
ately differentiated rcc tumor tissues and GluT5 (p=0.024). 
Patients with pelvic invasion showed increased GluT5 expres-
sion (p=0.039). A significant positive correlation was observed 
between GluT5 expression and patients with capsule breakage 
(p=0.019). related to histological type, GluT5 was found to 
present higher expression in clear rcc (p=0.001) (Table ii). 
Discussion
The study of GluT1-5 expression in rcc using Ta was viable 
and successful (16). Tumoral heterogeneity is partly obviated 
when evaluating different factors using Ta. 
This study investigated the expression and potential 
roles of five family glucose transporters (GLUT1-5) in RCC. 
Facilitative GluTs transport of glucose and increased expres-
sion of these transporters has been reported in rcc and other 
tumor types.
our results provide evidence that human rcc exhibits 
different levels and patterns of expression of GluT isoforms. 
Moreover, we found that a substantial proportion of the tumor 
specimens expressed increased levels of GluT5. 
although pre-clinical approaches to explore the role of 
GLUT5 in RCC are required, the significant correlation of 
immunohistochemical GluT5 expression in human tumor 
samples with rcc tumor differentiation grade, pelvic inva-
sion and capsule breakage (Table ii) suggests that fructose 
uptake mediated by GluT5 may play a role in the progression 
of rcc. 
a previous study (15) using molecular methods demon-
strated that GluT5 is overexpressed in clear cell rcc, 
although not significantly. However, we found significantly 
higher levels of GluT5 in clear cell rcc compared to chro-
mophobe and papillary histological types. 
GluT5 is the best characterized fructose transporter 
and is expressed in various cell types and tissues (intestine, 
testis, kidney, skeletal muscle, fat and brain) (11). among the 
seven members capable of transporting fructose, GluT5 is 
the sole transporter specific for fructose with no ability to 
transport glucose or galactose. currently, interest in GluT5 
is increasing due to a dramatic increase in the total fructose 
consumption in the human diet (10).
Fructose is the sweetest of all natural sugars. it is absorbed 
in the jejunum and transferred through the apical membrane of 
epithelial cells into the portal circulation. in the liver, fructose 
Table i. clinical characteristics of the patients.
Patient characteristics (n=80)
age (years)
  Mean 61.66
  range 34-87
Gender
  Male 53
  Female 27
Furhman grade
  1 15
  2 45
  3 16
  4   4
Histological typea
  clear cell carcinoma 57
  Papillary   6
  chromophobe 15
Tumors characteristics
capsule breakagea
  yes 12
  no 64
Pelvic invasion
  yes   9
  no 35
Vein invasion
  yes   9
  no 67
lymphatic invasion
  yes   2
  no 78
Hilar invasion
  yes   6
  no 70
aTwo samples had an unknown histologic type. capsule breakage, 
vein and hilar invasion could not be determined in four samples.
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is phosphorylated to fructose 1-phosphate and converted to 
glycerol 3-phosphate for the synthesis of glycerol, or metabo-
lized to acetyl-coa and incorpored into fatty acids. only a 
small portion is converted into glucose.
after the small intestine, the kidney expresses the majority 
of GluT5 protein in humans. GluT5 is present in the apical 
plasma membrane of S3 proximal tubule cells (18), where it 
has the potential to recapture fructose lost from glomerular 
  A   B
Figure 1. (a) GluT1 immunostaining in rcc. The tubular epithelium, glomerulus and interstices were negative (x40), while the intravascular erythrocytes 
were positive. (B) GluT2 immunostaining in rcc. Moderate cytoplasmic positivity was observed in 40% of tumor cells (x50).
Figure 2. (a) negative immunostaining for GluT3 in granular cell renal carcinoma (x40). (B) GluT4 immunostaining in rcc. light cytoplasmic positivity 
was observed in 10% of tumor cells.
  A   B
Figure 3. GluT5 immunostaining. (a) normal kidney with intense positivity in the apical pole of tubular epithelium. The glomerulus, the interstices and the 
vascular endothelium were negative (x40). (B) intense membrane positivity was observed in most tumor cells (x50). (c) intense cytoplasmic positivity was 
observed in most tumor cells (x50).
  A   B
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filtration. Differences in fructose concentration between 
filtrate and intracellular compartment determines the direc-
tion of fructose flux mediated by GLUT5. Kidney GLUT5 
protein levels are similar to those determined for GluT5 
in the intestine (19). Moreover, during the pre-natal period, 
levels of renal GluT5 protein are low, but rapidly increase 
during weaning, when its expression is also inducible by the 
fructose diet (20).
GluT5 is found in many tissues and its expression and 
activity are clearly regulated under malignant and non-
malignant pathological conditions. in the adult kidney, the 
regulation of GluT5 expression is dependent and activity 
under physiological condition is fructose diet and pathological 
conditions such as hypertension and type 1 diabetes.
GluT5 protein expression is affected by the development 
of tumors in certain organ systems. in general, oncogene-trans-
formed cells that exhibit a cancerous pattern also experience 
an increase in hexose transport by overexpressing specific 
sugar transporters. in the present study, GluT5 was overex-
pressed in the majority of RCCs. This finding is not supported 
by previous studies, which showed GluT1 to have the highest 
expression in rccs (21). GluT5 overexpression in rccs 
could indicate other pathways for hexose metabolism in many 
rccs. 
GluT5 was found overexpressed in a large-scale screening 
of the GluT transporters: brain, breast, colon, liver, lung, 
testis and uterus tumors (22).
a marked increase in GluT5 expression may indicate 
preferential utilization of fructose by rcc. This is associated 
with the need of tumors for an additional energy source. 
cancer cells maintain a high rate of glycolysis even in 
the presence of oxygen (Warburg effect) (23), probably due 
to the use of fermentative metabolism under the hypoxic 
conditions that develop in more aggressive tumors. GluT5 
overexpression may give rise to an increase in fructose 
uptake. conversely, the increase in fructose usage by tumor 
cells may lead to GluT5 overexpression in a positive feed-
back loop.
Table II. Relationship between GLUT1-5 expression and the pathological significance of RCC.
Pathological parameter Patient no. GluT2 GluT3 GluT4 GluT5
 (n=80) (range/p-value) (range/p-value) (range/p-value) (range/p-value)
differentiation degree
(Furhman grade)
  Well 15
  Moderate 45    44.81/0.024
  Poor 16   41.94/0.366
  indifferentiate   4 52.88/0.384 44.75/0.913
Pelvic invasion
  yes   9 48.89/0.329  50.28/0.240 54.56/0.039
  no 66
  undetermined   5  49.60/0.644
capsule breakage
  yes 12 45.38/0.576  52.00/0.080 54.75/0.019
  no 64
  undetermined   4  49.60/0.637
Tumor depth
  1 63
  2   4    56.63/0.437
  3 12 48.17/0.429
  4   1  63.00/0.595 77.00/0.029
Histological type
  clear cell 57  43.32/0.287 41.01/0.990 46.98/0.001
  Papillary   6 50.83/0.416
  chromophobe 15
  undetermined   2
Tumor localization
  right 40
  left 39 41.23/0.551 42.69/0.294 41.01/0.669 40.13/0.959
  undetermined   1
Vein invasion
  yes   9 45.50/0.783 63.00/0.321  63.00/0.312
  no 67   40.63/0.615
  undetermined   4
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Our findings support the importance of GLUT5 and the 
fructose metabolism in rcc. However, further studies must 
be conducted to elucidate the mechanism involved in sugar 
metabolism in rcc.
Acknowledgements
MBc has a grant from Fondo de investigación Sanitaria 
(FiS), instituto de Salud ‘carlos iii’. research in our Hospital 
is supported by the Fundación del complejo Hospitalario 
universitario a coruña (cHuac), Spain.
References
  1. Mathew a, devesa SS, Fraumeni JF Jr and chow WH: Global 
increases in kidney cancer incidence, 1973-1992. eur J cancer 
Prev 11: 171-178, 2002.
  2. Gupta K, Miller Jd, li JZ, russell MW and charbonneau c: 
epidemiologic and socioeconomic burden of metastatic renal 
cell carcinoma (mrcc): a literature review. cancer Treat rev 
34: 193-205, 2008.
  3. Ferlay J, autier P, Boniol M, Heanue M, colombet M and 
Boyle P: estimates of the cancer incidence and mortality in 
europe in 2006. ann oncol 18: 581-592, 2007.
  4. american cancer Society. estimated new cancer cases and deaths 
by sex, uS, 2008. american cancer Society: http://www.cancer.
org/downloads/stt/cFF2008Table_pg4.pdf. accessed June, 2009.
  5. isselbacher KJ: Sugar and amino acid transport by cells in 
culture – differences between normal and malignant cells. n 
engl J Med 286: 929-933, 1972.
  6. Hatanaka M: Transport of sugars in tumor cell membranes. 
Biochim Biophys acta 355: 77-104, 1974.
  7. Kresnik e, Gallowitsch HJ, Mikosch P, et al: Fluorine-18-
fluorodeoxyglucose positron emission tomography in the 
preoperative assessment of thyroid nodules in an endemic goiter 
area. Surgery 133: 294-299, 2003.
  8. Manolescu ar, Witkowska K, Kinnaird a, cessford T and 
cheeseman c: Facilitated hexose transporters: new perspectives 
on form and function. Physiology 22: 234-240, 2007.
  9. Mueckler Ma and rhoads dB: Facilitative glucose transporters. 
eur J Biochem 219: 713-725, 1994.
10. Schürmann a: insight into the ‘odd’ hexose transporters 
GluT3, GluT5 and GluT7. am J Physiol endocrinol Metab 
295: 225-226, 2008.
11. douard V and Ferraris rP: regulation of the fructose trans-
porter GluT5 in health and disease. am J Physiol endocrinol 
Metab 295: 227-237, 2008.
12. cantuaria G, Fagotti a, Ferradina G, Magalhaes a, nadji M, 
angioli r, Penalver M, Mancuso S and Scambia G: GluT-1 
expression in ovarian carcinoma: association with surival and 
response to chemotherapy. cancer 92: 1144-1150, 2001.
13. rogers eS, Macheda Ml, docherty Se, carty Md, 
Henderson Ma, Soeller Wc, Gibbs eM, James de and Best Jd: 
Identification of a novel glucose transporter-like protein- 
GluT-12. am J Physiol endocrinol Metab 282: 733-738, 2002.
14. younes M, lechago lV, Somoano Jr, Mosharaf M and 
lechago J: immunohistochemical detection of Glut3 in human 
tumors and normal tissues. anticancer res 17: 2747-2750, 1997.
15. Suganuma n, Segade F, Matsuzu K and Bowden dW: differential 
expression of facilitative glucose transporters in normal and 
tumour kidney tissues. BJu int 99: 1143-1149, 2007.
16. lidgren a, Bergh a, Grankvist K, rasmuson T and ljungberg B: 
Glucose transporter-1 expression in renal cell carcinoma and 
its correlation with hypoxia inducible factor-1α. BJu int 101: 
480-484, 2007.
 17. Miyakita H, Tokunaga M, onda H, usui y, Kinoshita H, 
Kawamura N and Yasuda S: Significance of 18F-fluorodeoxyg-
lucose positron emission tomography (FdG-PeT) for detection 
of renal cell carcinoma and immunohistochemical glucose trans-
porter 1 (GluT-1) expression in the cancer. int J urol 9: 15-18, 
2002.
18. Sugawara-yokoo M, Suzuki T, Matsuzaki T, naruse T and 
Takata K: Presence of fructose transporter GluT5 in the S3 
proximal tubules in the rat kidney. Kidney int 56: 1022-1028, 
1999.
19. corpe cP, Bovelander FJ, Munoz cM, Hoekstra JH, Simpson ia, 
Kwon o, levine M and Burant cF: cloning and functional char-
acterization of the mouse fructose transporter, GluT5. Biochim 
Biophys acta 1576: 191-197, 2002.
20. Burant cF and Saxena M: rapid reversible substrate regulation 
of fructose transporter expression in rat small intestine and 
kidney. am J Physiol Gastrointest liver Physiol 267: G71, 1994.
21. nagase y, Takata K, Moriyama n, aso y, Murakami T and 
Hirano H: immunohistochemical localization of glucose trans-
porters in human renal cell carcinoma. Br J urol 153: 798-801, 
1995.
22. Godoy a, ulloa V, rodriguez F, et al: differential subcellular 
distribution of glucose transporters GuT1-6 and GluT9 in 
human cancer: ultrastuctural localization of GluT1 and GluT5 
inbreast tumor tissues. J cell Physiol 270: 614-627, 2006.
23. Warburg o: on the origin of cancer cells. Science 123: 309-314, 
1956.
